Every 10-Q that Tempus AI (TEM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TEM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TEM filings page.
Tempus AI, Inc. reported Q2 2026 total net revenue of $382,486, up from $314,635 a year earlier. Diagnostics revenue was $289,333 and Data and applications revenue $93,153. Despite a loss from operations of $75,913, net income reached $5,642, supported by $102,757 of other income, including gains on marketable equity securities.
For the first half of 2026, revenue was $730,602, while the company recorded a net loss of $120,277 and used $80,802 of cash in operating activities. Cash, cash equivalents and restricted cash totaled $604,338 at June 30, 2026, and marketable equity securities were $216,377; the company believes these resources can fund its current operating plan for at least one year.
Tempus reshaped its capital structure, issuing $460,000 of 0.00% convertible senior notes due 2032 and previously $750,000 of 0.75% notes due 2030, while repaying long-term debt and a $100,000 revolving credit facility. Convertible senior notes, net, rose to $1,172,781, stock-based compensation reached $106,827 for the first half, and accumulated deficit increased to $2,516,139.
Tempus AI, Inc. reported total net revenue of 348,116 (in thousands) for the three months ended March 31, 2026, up from 255,737 (in thousands) a year earlier, driven by growth in both Diagnostics and Data and applications.
Diagnostics revenue reached 261,098 (in thousands), while Data and applications contributed 87,018 (in thousands). Net loss widened to 125,919 (in thousands), compared with 68,037 (in thousands) in the prior-year period, and basic net loss per share was 0.70.
Operating activities used cash of 73,277 (in thousands), but the company ended the quarter with cash, cash equivalents and restricted cash totaling 525,864 (in thousands) and total assets of 2,135,091 (in thousands). Management states that existing cash, cash equivalents and marketable equity securities as of March 31, 2026 will be sufficient to fund the current operating plan for at least one year.
Tempus AI (TEM) reported Q3 2025 results marked by rapid growth and continued investment. Total revenue reached $334.2 million, up from $180.9 million a year ago, driven by Genomics $252.9 million and Data and services $81.3 million. Loss from operations was $61.0 million and net loss was $80.0 million, or $0.46 per share.
Balance sheet and cash flows reflected major 2025 actions. Cash and cash equivalents were $655.9 million, with total assets at $2.28 billion. The company issued convertible senior notes, net of discount, of $726.5 million, drew $98.0 million on its revolver, raised $195.5 million via an at‑the‑market equity program, and repaid $276.9 million of long‑term debt. Operating cash outflow was $181.3 million year‑to‑date.
Strategic acquisitions expanded capabilities. Tempus closed the Ambry Genetics acquisition for $375.0 million in cash plus 4,843,136 Class A shares, and acquired Paige.AI for $102.7 million, including 1,272,151 shares and $3.0 million cash, increasing goodwill and intangibles. Remaining performance obligations on limited multi‑year contracts were $360.2 million. As of October 30, 2025, Class A shares outstanding were 172,863,470 and Class B were 5,043,789.
Tempus AI (TEM) Q2 2025 10-Q highlights:
- Revenue doubled to $314.6 M (+89% YoY); Genomics up 115% to $241.8 M and Data & Services up 36% to $72.8 M.
- Losses narrowed sharply. Net loss was $42.8 M vs. $552.2 M prior-year; loss per share improved to $(0.25) from $(6.86). Six-month loss fell 82% to $110.9 M.
- Margin trend: Gross margin rose to 62.0% from 45.5% as revenue growth outpaced cost of revenue.
- Cash flow improving. Operating cash outflow was $61.5 M versus $198.5 M YoY.
- Balance sheet transformed by M&A. Ambry Genetics acquisition (closed Feb 2025) added $695 M in assets, boosting goodwill/intangibles to $713 M. Total assets $1.63 B (+76% YTD); equity $309.6 M vs. $56.3 M at YE-24.
- Leverage increased. Long-term debt rose to $471.7 M (including new $100 M revolver); convertible note now $226.3 M. Cash & equivalents declined to $186.3 M from $341.0 M due to acquisition spend.
- The company remains an emerging growth company but expects to become a large accelerated filer as of year-end 2025.
Outlook implications: Rapid top-line expansion and integration of Ambry broaden TEM’s test menu and dataset, but higher leverage and ongoing losses keep profitability and liquidity key watch points.